

7<sup>th</sup> European Congress on Tropical Medicine  
and International Health (ECTMIH)  
Barcelona, Spain 3-6 October 2011

BEST  
SCIENCE  
FOR THE MOST  
NEGLECTED

# Meet the **DNDi** network at ECTMIH!

## Patient Needs-Driven R&D for Neglected Diseases

- List of Sessions
- Visit our joint **DNDi-MSF booth #17**



[www.dndi.org](http://www.dndi.org)

**DNDi**

Drugs for Neglected Diseases *initiative*

*Iniciativa* Medicamentos para Enfermedades Olvidadas



## **MONDAY OCTOBER 3<sup>rd</sup>**

### **11.00-12.30: Room 1: T1.1 P1 Parallel Session**

#### **Global trends in the epidemiology of malaria and advances towards elimination**

Speaker (not exhaustive):

- Highlights of the Malaria Elimination research agenda (MaIERA)  
*Marcel Tanner*, Director, Swiss Tropical and Public Health Institute (Swiss TPH); Chair of the Board of Directors, Drugs for Neglected Diseases *initiative* (DNDi)

### **11.00-12.30: Room 3: T1.3 M1 Main Session**

#### **Improving the quality of diagnostic work-up for neglected tropical diseases, a syndromic approach (NIDIAG)**

Speakers (not exhaustive):

- The need for better quality of diagnostic workup in NID  
*François Chappuis*, Medical Advisor, Médecins Sans Frontières, Switzerland; Associate Professor, Geneva University Hospitals, Switzerland; member of DNDi's Scientific Advisory Committee
- The febrile syndrome; recent advances in antigen detection tests for visceral leishmaniasis  
*Shyam Sundar*, Professor of Medicine, Institute of Medical Sciences, Banaras Hindu University, India; key DNDi partner in VL clinical studies

### **15.00-16.30: Plenary Room: T1.3 M3 Main Session**

#### **DNDi's session: Drug development for Kinetoplastids**

Chairs:

- *Simon Croft*, Professor of Parasitology/Head of Faculty, London School of Hygiene & Tropical Medicine (LSHTM); member of DNDi's Scientific Advisory Committee
- *Jean Jannin*, Coordinator, Innovative & Intensified Disease Management, WHO/NTD

Speakers:

- Latest drug development and innovation for kinetoplastid diseases  
*Nathalie Strub Wourgaft*, Medical Director, Drugs for Neglected Diseases *initiative* (DNDi)
- HAT: in-hospital safety of NECT use in African children, pregnant and breast-feeding women  
*Olaf Valverde*, Medical Manager, Drugs for Neglected Diseases *initiative* (DNDi)
- New drug candidates and innovation for HAT: from discovery to promising candidates, illustrated by Oxaboroles development  
*Yves Ribeill*, President & CEO, Scynexis
- Chagas portfolio  
*Isabela Ribeiro*, Head of Chagas Clinical Programme, Drugs for Neglected Diseases *initiative* (DNDi)



- Treatment modalities for visceral leishmaniasis (Kala-Azar) under field routine program conditions  
*M<sup>o</sup> Angeles Lima*, Tropical Medicine Advisor, Médecins sans Frontières (MSF) NTDs working group

**Poster – Session 1 (Monday 3<sup>rd</sup> until Tuesday 4<sup>th</sup>)**

- **Poster # 1.3-034:** Single-dose Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Fexinidazole  
*Antoine Tarral, Séverine Blesson, Olaf Valverde, Lionel Hovsepian, Eric Even, Nathalie Strub Wourgaft*
- **Poster # 1.1-053:** Haematological parameters in paediatric uncomplicated *falciparum* malaria in Sub-Saharan Africa  
*Piero Olliaro, Abdoulaye Djimdé, Grant Dorsey, Corine Karema, Andreas Mårtensson, Jean-Louis Ndiaye, Sodiomon B Sirima, Michel Vaillant, Julien Zwang*
- **Poster # 1.1-024:** Antimalarial drug safety information generated through routine monitoring in a rural health centre in South-western Senegal  
*Philippe Brasseur, Malick Badiane, Moustafa Cisse, Patrice Agnamey, Michel Vaillant, Piero L Olliaro*

**TUESDAY OCTOBER 4<sup>th</sup>**

**11.00-12.30: Plenary Room T1.3 M4 Main Session**

**The diagnosis and treatment of leishmaniases (Laboratorios Leti)**

Chairs:

- *Jorge Alvar*, Medical Officer, WHO Leishmaniasis Program, World Health Organization (WHO)
- *François Chappuis*, Medical Advisor, Médecins Sans Frontières, Switzerland; Associate Professor, Geneva University Hospitals, Switzerland; member of DNDi's Scientific Advisory Committee

Speakers (not exhaustive):

- Visceral leishmaniasis elimination initiatives in South East Asia and Brazil  
*Jorge Alvar*, Medical Officer, WHO Leishmaniasis Program, World Health Organization (WHO)
- New perspectives on policies for control of visceral leishmaniasis in India  
*Shyam Sundar*, Professor of Medicine, Institute of Medical Sciences, Banaras Hindu University, India; key DNDi partner in VL clinical studies
- Treatment of Cutaneous Leishmaniasis : a tri-component approach  
*Farrokh Modabber*, Senior Advisor for Leishmaniasis, Drugs for Neglected Diseases initiative (DNDi)



**12.30 – 14.00: Room 3 T4 P1-09 Parallel Session**

**Oral communications on health systems and resources**

Speaker (not exhaustive):

- Regional Platform to reinforce capacity for clinical trials in Human African Trypanosomiasis (HAT Platform): Five years contributing to improve research  
*Augustin Kadima Ebeja*, Coordinator, HAT Platform, Kinshasa-Congo

**16.30-18.00: Room 6 T1.2 M3 Main Session**

**Institute of Tropical Medicine, Antwerp, Belgium and DNDi session:  
Visceral leishmaniasis-HIV coinfection: current challenges and perspectives**

Chairs:

- *Jorge Alvar*, Medical Officer, WHO Leishmaniasis Program, World Health Organization (WHO)
- *Ed Zijlstra*, Senior Consultant in Leishmaniasis, Drugs for Neglected Diseases *initiative* (DNDi)

Speakers:

- Introduction  
*Ed Zijlstra*, Senior Consultant in Leishmaniasis, Drugs for Neglected Diseases *initiative* (DNDi)
- The Mediterranean experience: lessons learned and current challenges  
*Rogelio López-Vélez*, Associate Professor, Hospital Ramón y Cajal, Madrid
- Experience from the field  
*Koert Ritmeijer*, Health Advisor, Médecins Sans Frontières (MSF)
- VL-HIV coinfection in East-Africa  
*Ermias Diro*, Medical Coordinator, Gondar University, Ethiopia
- VL-HIV coinfection: emerging in South-America  
*José Angelo Lauletta Lindoso*, Researcher, Institute of Infectology Emilio Ribas and Laboratory of Seroepidemiology from Institute of Tropical Medicine from São Paulo, Brazil
- Recent HIV-VL clinical research initiatives in East-Africa  
*Johan van Griensven*, Researcher, ITM Antwerp
- Issues to be addressed and discussion  
*Jorge Alvar*, Medical Officer, WHO Leishmaniasis Program, World Health Organization (WHO)

**Poster – Session 1 (Monday 3<sup>rd</sup> until Tuesday 4<sup>th</sup>)**

- **Poster # 1.3-034:** Single-dose Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Fexinidazole  
*Antoine Tarral*, *Séverine Blesson*, *Olaf Valverde*, *Lionel Hovsepian*, *Eric Even*, *Nathalie Strub Wourgaft*



- **Poster # 1.1-053:** Haematological parameters in paediatric uncomplicated *falciparum* malaria in Sub-Saharan Africa  
*Piero Olliaro, Abdoulaye Djimdé, Grant Dorsey, Corine Karema, Andreas Mårtensson, Jean-Louis Ndiaye, Sodiomon B Sirima, Michel Vaillant, Julien Zwang*
- **Poster # 1.1-024:** Antimalarial drug safety information generated through routine monitoring in a rural health centre in South-western Senegal  
*Philippe Brasseur, Malick Badiane, Moustafa Cisse, Patrice Agnamey, Michel Vaillant, Piero Olliaro*

## WEDNESDAY OCTOBER 5<sup>th</sup>

**9.00-10.30: Plenary room Plenary Session**

### **The Science of Elimination**

The debate over what constitutes eradication has been ongoing for decades. In trying to establish clear definitions, a 1997 forum, one in a series of brainstorming sessions called the Dahlem Workshops, stated that “elimination” was to become the word for anything less than the global target, while “eradication” was reserved for pathogens completely out of the world, excluding any remaining stocks in laboratory freezers. Thirty years later, smallpox remains the only human disease to have been truly eradicated. This accomplishment has inspired the global community to aim for other pathogens to be wiped off the planet, and two eradication campaigns for polio and malaria were launched following its wave, although neither has been attained. Today different stakeholders are questioning whether eradication should be our ultimate goal given the resources needed to make it a reality.

Chair:

- *Marcel Tanner*, Director, Swiss Tropical and Public Health Institute (Swiss TPH); Chair of the Board of Directors, Drugs for Neglected Diseases *initiative* (DNDi)

Speakers:

- *Bernard Pécoul*, Executive Director, Drugs for Neglected Diseases *initiative* (DNDi)
- *Pedro Alonso*, Professor and Director, Institute for Global Health of Barcelona and Barcelona Centre for International Health Research (Hospital Clínic - University of Barcelona), Spain
- *Lorenzo Savioli*, Director, Department of Control of Neglected Tropical Diseases, World Health Organization (WHO)
- *Rose Leke*, Chair, African Regional Certification Commission



**15.00-16.30: Room 3: T1.3 P6 Parallel Session**

**Other issues in NTDs:**

Chair: *To be confirmed*

Speaker (not exhaustive):

- Development of Flubendazole as a macrofilaricide treatment for filarial infections  
*Rob Don*, Discovery & Preclinical Director, Drugs for Neglected Diseases initiative (DNDi)

**15.00-16.30: Room 4 T1.1 M4 Main Session**

**Advances and challenges in the treatment of malaria:**

Chairs:

- *Tim Wells*, Chief Scientific Officer, Medicines for Malaria Venture (MMV)
- *Nicholas Cammack*, Vice President and Head, GSK Tres Cantos, Spain

Speaker (not exhaustive):

- ASMQ FDC a simple and child friendly ACT developed for Asia and Latin America  
*Jean-René Kiechel*, Senior Pharma Advisor & Product Manager, Drugs for Neglected Diseases initiative (DNDi)

**16.30-18.00 Room 1 T1.3 P7 Parallel Session**

**Human trypanosomiasis**

Chairs:

- *Faustino Torrico*, Professor of Parasitic Diseases and Infectious Disease, University of San Simon, Bolivia; member of DNDi's Scientific Advisory Committee
- *Joaquim Gascón*, Head Of Tropical Medicine Section, Barcelona Centre for International Health Research (Hospital Clínic -University of Barcelona), Spain

Speaker:

- Rationale and design of a proof-of-concept Phase II clinical study of E1224, a new drug candidate for chronic Chagas disease  
*Faustino Torrico*, Professor of Parasitic Diseases and Infectious Disease, University of San Simon, Bolivia; member of DNDi's Scientific Advisory Committee

**Poster – Session 2 (Wednesday 5<sup>th</sup> until Thursday 6<sup>th</sup>)**

- **Poster # 4.3-041:** Three clinical research platforms in Africa and Latin America to build sustainable research capacities  
*Augustin Ebeja*, HAT Platform Coordinator, Drugs for Neglected Diseases initiative (DNDi) DRC
- **Poster # 1.3-190:** Population Pharmacokinetics of Benznidazole in Children with Chagas' Disease  
*Isabela Ribeiro*, Head of Chagas Clinical Programme, Drugs for Neglected Diseases initiative (DNDi)



- **Poster # 5.3-036:** Effect of artesunate-mefloquine fixed-dose combination in malaria transmission in Amazon basin communities  
*Ana Carolina Santelli, Isabela Ribeiro, André Daher, Marcos Boulos, Paola Marchesini, Roseli La Corte, Marize Barbosa Freire de Lucena, Izanelda Magalhães, Antonio Ponce de Leon, Washington Junger, Jean-René Kiechel, José Lázaro de Brito Ladislau*
- **Poster # 1.1-089:** Clinical and laboratory safety of artesunate-amodiaquine and comparator treatments for uncomplicated falciparum malaria - an individual patient data analysis of randomised controlled trials  
*Piero Olliaro, JL Ndiaye, SB Sirima, A Mårtensson, A Djimdé, G Dorsey, C Karema, J Zwang*
- **Poster # 1.1-091:** Changing malaria patterns - a 15-year study in a rural district of Southern Senegal (1996-2010)  
*Michel Vaillant, Piero Olliaro, Moustafa Cisse, Malick Badiane, Philippe Brasseur*
- **Poster # 4.3-049:** Health Research policy in southern Sudan  
*Richard Lino Lako, Samson Baba, Lea Moja, Ministry of Health Government of Southern Sudan, presented by Augustin Ebeja, DNDi DRC*

## THURSDAY OCTOBER 6<sup>th</sup>

### Poster – Session 2 (Wednesday 5<sup>th</sup> until Thursday 6<sup>th</sup>)

- **Poster # 4.3-041:** Three clinical research platforms in Africa and Latin America to build sustainable research capacities  
*Augustin Ebeja, HAT Platform Coordinator, Drugs for Neglected Diseases initiative (DNDi) DRC*
- **Poster # 1.3-190:** Population Pharmacokinetics of Benznidazole in Children with Chagas' Disease  
*Isabela Ribeiro, Head of Chagas Clinical Programme, Drugs for Neglected Diseases initiative (DNDi)*
- **Poster # 5.3-036:** Effect of artesunate-mefloquine fixed-dose combination in malaria transmission in Amazon basin communities  
*Ana Carolina Santelli, Isabela Ribeiro, André Daher, Marcos Boulos, Paola Marchesini, Roseli La Corte, Marize Barbosa Freire de Lucena, Izanelda Magalhães, Antonio Ponce de Leon, Washington Junger, Jean-René Kiechel, José Lázaro de Brito Ladislau*
- **Poster # 1.1-089:** Clinical and laboratory safety of artesunate-amodiaquine and comparator treatments for uncomplicated falciparum malaria - an individual patient data analysis of randomised controlled trials  
*Piero Olliaro, JL Ndiaye, SB Sirima, A Mårtensson, A Djimdé, G Dorsey, C Karema, J Zwang*
- **Poster # 1.1-091:** Changing malaria patterns - a 15-year study in a rural district of Southern Senegal (1996-2010)  
*Michel Vaillant, Piero Olliaro, Moustafa Cisse, Malick Badiane, Philippe Brasseur*
- **Poster # 4.3-049:** Health Research policy in southern Sudan  
*Richard Lino Lako, Samson Baba, Lea Moja, Ministry of Health Government of Southern Sudan, presented by Augustin Ebeja, DNDi DRC*

# DNDi

Drugs for Neglected Diseases *initiative*

Best science  
for the most neglected

## DNDi

15 Chemin Louis-Dunant  
1202 Geneva  
Switzerland  
Tel: +41 22 906 9230  
Fax: +41 22 906 9231  
dndi@dndi.org  
www.dndi.org

## Regional Offices

### DNDi AFRICA

c/o Centre for Clinical Research  
Kenya Medical Research Institute  
PO Box 20778  
KNH 00202 Nairobi  
Kenya  
Tel: +254 20 273 0076

### DNDi LATIN AMERICA

Jardim Botânico-Rio de Janeiro  
Rua Santa Heloisa 5  
Rio de Janeiro, RJ 22460-080  
Brazil  
Tel: +55 21 2215 2941  
www.dndi.org.br

### DNDi INDIA

c/o Indian Council of Medical  
Research  
2nd Campus – Room No 3, 1st Floor  
TB Association Building  
3, Red Cross Road  
New Delhi 110-001  
India  
Tel: +91 11 2373 1635

### DNDi JAPAN

3-1-4 Nishi-Shinjuku  
Shinjuku-ku Tokyo 160-0023  
Japan  
Tel: +81 3 6304 5588  
www.dndijapan.org

### DNDi MALAYSIA

c/o Centre for Drug Research  
University Sains Malaysia  
11800 Minden – Pulau Pinang  
Malaysia  
Tel: +60 4 657 9022

## Project Support Office

### DNDi DRC

Av Révolution n°04  
Quartier Socimat  
La Gombe, Kinshasa  
Democratic Republic  
of the Congo  
Tel: +243 81 011 81 31

## Affiliate

### DNDi NORTH AMERICA

40 Wall Street, 24th Floor  
New York, NY 10005  
USA  
Tel: +1 646 616 8680  
www.dndina.org